Intractable middle ear effusion in EGPA patients might cause permanent hearing loss: a case-control study.
Noeul KangJoongbo ShinYang-Sun ChoJin-Young LeeByung-Jae LeeDong-Chull ChoiPublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2022)
MEE is a common but frequently neglected condition in EGPA which is often intractable. The maintenance steroid dose should be adequately adjusted to control MEE and to prevent from progressive hearing loss. Novel biologic agents possibly have a role in controlling MEE in EGPA.